新型RESILIA组织主动脉生物瓣的中期结局:COMMENCE试验4年结果
COMMENCE试验是一项前瞻性、多国、多中心(27家)、单臂的FDA IDE研究,评估新型RESILIA组织主动脉生物瓣(Edwards Pericardial Aortic Bioprosthesis, Model 11000A)的安全性和有效性。2013年1月至2016年3月共纳入689例患者,平均年龄67.0±11.6岁,平均STS预测死亡风险2.0%±1.8%,随访3.7±1.2年(中位4年)。4年全因死亡率 actuarial 自由度为91.9%(95%CI 89.7%-94.1%),无结构性瓣膜 deterioration 事件,血流动力学性能良好。
要点
- 4年全因死亡 actuarial 自由度91.9%,早期全因死亡率1.2%。
- 4年无中度及以上瓣膜反流 freedom 99.7%,无结构性瓣膜 deterioration。
- 新型RESILIA组织未出现意外早期血栓事件或非钙化性瓣膜 failure。
核心结论
- 该新型RESILIA组织主动脉生物瓣在4年时安全性和血流动力学性能良好,未出现意外早期血栓事件或非钙化性结构性瓣膜 deterioration。
研究设计与样本
- 前瞻性、多国、多中心(n=27)、单臂、FDA IDE试验(COMMENCE),2013年1月至2016年3月共纳入689例接受临床指示的主动脉瓣置换患者。
- 平均年龄67.0±11.6岁,平均STS预测死亡风险2.0%±1.8%,随访3.7±1.2年,中位随访4年,总随访2533患者年。
主要发现
- 早期全因死亡率1.2%,血栓栓塞2.3%,所有出血1.0%,重大瓣周漏0.1%。
- 1年和4年全因死亡 actuarial 自由度分别为97.7%(95%CI 96.5%-98.8%)和91.9%(95%CI 89.7%-94.1%)。
- 4年时NYHA功能分级较基线改善者占63.0%,有效瓣口面积1.5±0.5 cm2,平均压差11.0±5.6 mm Hg。
- 4年无中度及以上经瓣反流 freedom 为99.7%,无结构性瓣膜 deterioration 事件。
临床怎么用
- 对于有主动脉瓣置换指征的患者,该新型RESILIA组织生物瓣在4年随访中表现出良好的安全性和血流动力学结果,可作为生物瓣选择之一。
局限性
- 单臂研究设计,缺乏随机对照比较;随访时间仅4年,为中期结果,长期耐久性需进一步观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The COMMENCE trial was conducted to evaluate the safety and effectiveness of an aortic bioprosthesis with novel RESILIA tissue (Edwards Lifesciences, Irvine, Calif). Reports of early noncalcific valve failure resulting from thrombosis or leaflet tears in other valves warrant careful evaluation of early valve performance. METHODS: Patients underwent clinically indicated surgical aortic valve replacement with the Edwards Pericardial Aortic Bioprosthesis, Model 11000A (Edwards Lifesciences) in a prospective, multinational, multicenter (n = 27), single-arm, Food and Drug Administration Investigational Device Exemption trial. Events were adjudicated by an independent clinical events committee; echocardiograms were analyzed by an independent core laboratory. RESULTS: Between January 2013 and March 2016, 689 patients received the study valve. Mean age was 67.0 ± 11.6 years. Mean Society of Thoracic Surgeons predicted risk of mortality was 2.0% ± 1.8%. Follow-up duration was 3.7 ± 1.2 years, with a total of 2533 patient years of follow-up and a median follow-up of 4 years. Early all-cause mortality was 1.2%, thromboembolism 2.3%, all bleeding 1.0%, and major paravalvular leak 0.1%. One- and 4-year actuarial freedom from all-cause mortality was 97.7% (95% confidence interval, 96.5%-98.8%) and 91.9% (95% confidence interval, 89.7%-94.1%), respectively. At 4 years, New York Heart Association functional class improved compared with baseline in 63.0%, effective orifice area was 1.5 ± 0.5 cm2, and mean gradient was 11.0 ± 5.6 mm Hg. Freedom from moderate or greater transvalvular insufficiency was 99.7%. There were no events of structural valve deterioration. CONCLUSIONS: Safety and hemodynamic performance of this aortic bioprosthesis with RESILIA tissue at 4 years are favorable. This novel tissue does not appear to result in unexpected early thrombosis events or noncalcific structural valve deterioration.
引用
- Johnston DR, Griffith BP, Puskas JD, et al. Intermediate-term outcomes of aortic valve replacement using a bioprosthesis with a novel tissue. J Thorac Cardiovasc Surg. 2020. PMID: 32340804. doi:10.1016/j.jtcvs.2020.01.095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。